



e-ISSN: 2319-8753 | p-ISSN: 2347-6710

# IJIRSET

International Journal of Innovative Research in  
**SCIENCE | ENGINEERING | TECHNOLOGY**



# INTERNATIONAL JOURNAL OF INNOVATIVE RESEARCH

IN SCIENCE | ENGINEERING | TECHNOLOGY

Volume 13, Issue 12, December 2024

**ISSN** INTERNATIONAL  
STANDARD  
SERIAL  
NUMBER  
INDIA

**Impact Factor: 8.524**

9940 572 462

6381 907 438

[ijirset@gmail.com](mailto:ijirset@gmail.com)

[www.ijirset.com](http://www.ijirset.com)

# Evolution, Challenges, and Strategies of Mankind in the Global Pharmaceutical Industry: A Comprehensive Analysis

Kartik Sisodia, Dr. R. Thanga Prashath

Department of Management, NIMS School of Business Studies, NIMS University, Jaipur, India

Associate Professor, NIMS School of Business Studies, NIMS University, Jaipur, India

**ABSTRACT:** The global pharmaceutical industry has undergone significant transformation over the past century, driven by advancements in science, technology, and regulatory frameworks. This study explores the evolution of the pharmaceutical industry, the challenges it faces, and the strategies it employs to address these challenges. It examines the historical development of the industry, highlighting key milestones such as the advent of synthetic drugs, the rise of biotechnology, and the impact of globalization on drug production and distribution. The study also addresses current challenges, including complex regulatory environments, rising drug development costs, pricing pressures, and global health crises like the COVID-19 pandemic and antimicrobial resistance.

Furthermore, the research identifies strategic responses to these challenges, focusing on innovation in research and development (R&D), regulatory harmonization, sustainability practices, and efforts to enhance global access to medicines. By analysing both qualitative and quantitative data, this study provides insights into the evolving dynamics of the pharmaceutical industry and offers actionable recommendations for stakeholders, including pharmaceutical companies, policymakers, and global organizations. The findings underscore the importance of continued innovation, collaboration, and sustainability to ensure that the pharmaceutical industry remains adaptable and responsive to the ever-changing global health landscape.

Ultimately, this research contributes to the broader understanding of how the pharmaceutical industry can navigate its complex challenges while advancing global health outcomes.

**KEY WORDS:** Pharmaceutical Industry, Evolution, Global Health, Drug Development, Regulatory Challenges, Biotechnology, Innovation Strategies

## I. INTRODUCTION

The global pharmaceutical industry has been a cornerstone of human health and well-being for centuries, with its evolution shaped by advances in science, technology, and the shifting needs of society. From the discovery of ancient remedies and the advent of modern pharmacology to the development of biotechnological innovations, the pharmaceutical industry has played a pivotal role in enhancing life expectancy and combating diseases. However, as the world faces complex health challenges such as the COVID-19 pandemic, antimicrobial resistance, and emerging chronic diseases, the industry is under increasing pressure to adapt and innovate.

This study explores the evolution, challenges, and strategies of mankind in the global pharmaceutical industry, with a focus on how the sector has evolved from its early foundations to the present day and the strategies that pharmaceutical companies and global health organizations use to address the rapidly changing healthcare landscape. The evolution of the industry has been marked by critical breakthroughs such as the discovery of antibiotics, the development of vaccines, and the emergence of personalized medicine. Alongside these advancements, however, the industry faces numerous challenges, including escalating drug development costs, regulatory hurdles, ethical concerns over pricing, and disparities in access to medicines across the world.

One of the most pressing issues today is the balance between innovation and affordability. While the development of new treatments and therapies is crucial, the costs associated with drug discovery, production, and distribution have been

rising, making it more difficult for some populations to access essential medicines. Furthermore, the global pharmaceutical landscape is increasingly influenced by technological advances such as artificial intelligence (AI), data analytics, and biotechnology, which are revolutionizing drug discovery and development. However, these innovations also introduce new complexities in terms of regulation, data privacy, and ethical concerns.

To navigate these challenges, pharmaceutical companies have adopted a range of strategies, including collaboration with academic institutions, increased investment in R&D, and the development of sustainable manufacturing practices. Global organizations like the World Health Organization (WHO) and national health bodies also play a critical role in shaping policies that aim to improve access to medicines and ensure equitable distribution, especially in low- and middle-income countries.

This research aims to provide a comprehensive overview of the global pharmaceutical industry's evolution, analyse the key challenges it faces today, and explore the strategies being employed to overcome these obstacles. By examining both the historical and current state of the industry, this study seeks to offer insights into how the pharmaceutical sector can continue to meet the evolving health needs of the global population, while ensuring that innovation and accessibility remain at the forefront of the industry's future development.

## II. LITERATURE REVIEW

### 1. Introduction to the Pharmaceutical Industry

The pharmaceutical industry has undergone significant evolution over the past century, influenced by technological advancements, societal changes, and global health crises. Early pharmaceutical practices were rooted in herbal medicine and traditional healing, but with the rise of chemical synthesis in the 19th century, modern pharmacology began to take shape. The 20th century saw the rise of major pharmaceutical companies and the development of mass-produced life-saving drugs, which transformed public health. As the industry grew, so too did its challenges, including regulatory complexity, rising costs, and the increasing need for innovation in drug development.

### 2. Evolution of the Pharmaceutical Industry

The early pharmaceutical industry was heavily influenced by natural remedies, but by the 19th century, the increasing understanding of chemistry and biology led to the isolation and synthesis of medicinal compounds (Cohen, 2020). The introduction of key drugs such as morphine, quinine, and vaccines set the stage for modern pharmaceutical development. According to Godlee et al. (2019), the 20th century marked a turning point with the discovery of penicillin, which paved the way for antibiotic treatment, saving millions of lives worldwide.

### 3. Early History and Industrialization

With the establishment of pharmaceutical giants like Merck and Pfizer, the industry became more industrialized, with production and distribution moving beyond local pharmacies to large-scale manufacturing facilities. The development of regulatory agencies, such as the U.S. Food and Drug Administration (FDA), in the early 20th century ensured that drugs were tested for safety and efficacy before reaching the market (Smith, 2017).

### 4. The Biotechnology Revolution and Globalization

The biotechnology revolution in the late 20th century introduced genetic engineering, leading to the production of genetically engineered drugs, such as insulin and growth hormones (Jones & Richards, 2021). Biotech companies, alongside traditional pharmaceutical companies, began to dominate the industry, with specialized treatments like monoclonal antibodies becoming common (Sharma, 2018). Globalization facilitated the expansion of pharmaceutical companies across borders, with manufacturing, research, and distribution increasingly interconnected.

### 5. Challenges in the Pharmaceutical Industry

A significant challenge for the pharmaceutical industry is the complex and ever-changing regulatory environment. Different countries have unique regulations, making it difficult for multinational companies to navigate the approval processes (Harris, 2022). For instance, the approval of drugs in the U.S. by the FDA may differ from the European Medicines Agency's (EMA) criteria, causing delays and increased costs. According to Patel et al. (2020), these discrepancies often result in higher expenses for companies trying to market drugs globally.

## 6. Regulatory and Compliance Issues

Additionally, intellectual property (IP) issues, including patent expirations and the rise of generics, pose substantial challenges to revenue generation. As patents for blockbuster drugs expire, generics flood the market, often at significantly lower prices, reducing the profitability of the original innovators (Williams & Parker, 2021).

## 7. Rising Drug Costs and Pricing Pressures

The rising cost of drug development and the pricing of pharmaceuticals have become contentious issues. A study by McKinsey & Company (2023) highlighted that the average cost of developing a new drug has risen dramatically over the last few decades, now exceeding \$2.6 billion per drug. This increase in cost is primarily due to the lengthy clinical trial phases, regulatory hurdles, and the high failure rates of experimental drugs. As a result, pharmaceutical companies are under pressure to price drugs in a way that balances development costs with accessibility, especially in developing countries where affordability is a key concern (Sullivan & Thomas, 2021).

## 8. Global marketing of lifesaving Drugs: An analogical model:

The ethical dilemma surrounding drug pricing has led to increasing calls for price regulation, particularly in the United States. Research by Williams et al. (2022) emphasizes the growing public outcry over the prices of life-saving drugs, such as insulin, leading to increased scrutiny of pharmaceutical companies by governments and consumer advocacy groups.

## 9. Public Health Crises and Pandemic Response

Public health crises, such as the COVID-19 pandemic, have further exposed vulnerabilities in the pharmaceutical industry. While the rapid development of vaccines was a remarkable success, the industry faced numerous logistical challenges in terms of production, distribution, and access. According to Gupta et al. (2021), the COVID-19 pandemic revealed the difficulties in ensuring equitable access to vaccines, particularly for low- and middle-income countries.

10. Moreover, antimicrobial resistance (AMR) remains a growing concern, as the overuse of antibiotics has led to the development of resistant pathogens. The pharmaceutical industry faces the challenge of developing new antibiotics while combating the decline in investment in this area due to limited profitability (Carter & Shaw, 2020).

## 11. Technological Disruptions and the Role of AI

Technological advancements, particularly the rise of artificial intelligence (AI) and machine learning, are transforming the pharmaceutical landscape. AI has shown great potential in drug discovery by predicting molecular structures and identifying potential drug candidates much faster than traditional methods (Thompson & Green, 2021). According to a report by McKinsey (2022), AI and data analytics are expected to reduce drug discovery timelines and improve the precision of clinical trials. However, concerns about data privacy, algorithmic bias, and regulatory approval for AI-based drug development remain significant barriers (Patel & Singh, 2020).

## 12. Innovation and Research & Development (R&D)

In order to address the challenges of high drug development costs and the growing demand for new treatments, the pharmaceutical industry has focused on fostering innovation. Collaboration between pharmaceutical companies and academic institutions is becoming more common, with public-private partnerships accelerating drug development (Kumar & Singh, 2021).

## 13. Strategies for Overcoming Challenges:

Personalized medicine, which tailors treatments based on an individual's genetic makeup, has emerged as a promising strategy to improve efficacy and reduce side effects (Miller & Grant, 2022).

## 14. Regulatory Reform and Harmonization

Harmonizing global regulatory standards is a critical strategy to reduce delays and costs associated with drug approvals. Initiatives such as the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) aim to streamline the approval processes and create uniformity across regions (Harris & Lane, 2020). Furthermore, governments can work together to establish common pricing policies that ensure drugs remain affordable without undermining industry sustainability (Robinson et al., 2021).

## 15. Addressing Global Health Inequities

The pharmaceutical industry is increasingly adopting strategies to expand access to medicines in developing countries. By partnering with non-governmental organizations (NGOs) and international bodies like the World Health Organization (WHO), pharmaceutical companies are working to increase the availability of essential medicines at affordable prices (Gates & Walters, 2021). Innovative pricing models, such as tiered pricing and patent pools, are being explored to provide affordable treatments to underserved populations.

## 16. Sustainability and Green Practices

Sustainability is an emerging concern, with pharmaceutical companies under pressure to reduce their environmental footprint. Companies are adopting green chemistry practices to minimize waste and reduce energy consumption in manufacturing. Additionally, there is growing interest in sustainable packaging and reducing plastic waste in the industry (Walker & Lee, 2020). Research into biodegradable alternatives to traditional packaging materials is gaining traction.

## 1. Evolution of the Pharmaceutical Industry

### 1.1 Early Beginnings (Pre-20th Century)

- Traditional herbal medicine and early pharmacology
- Emergence of chemical synthesis and the birth of modern pharmaceuticals in the 19th century
- Key early developments (e.g., morphine, quinine, and vaccines)

### 1.2 The 20th Century: Industrialization and Innovation

- The pharmaceutical industry's rise during the early 1900s with mass production of penicillin
- The growth of multinational pharmaceutical companies (e.g., Merck, Pfizer, and GlaxoSmithKline)
- Regulatory frameworks: The introduction of government oversight (FDA, EMA) to ensure drug safety and efficacy
- Technological breakthroughs, such as the discovery of insulin, antibiotics, and the development of vaccines

### 1.3 Late 20th Century to Present: Biotechnology and Globalization

- The biotechnology revolution and genetic engineering
- Development of highly specialized and targeted therapies (e.g., monoclonal antibodies, personalized medicine)
- The rise of global supply chains and the interdependence of pharmaceutical manufacturing
- Impact of globalization on research, development, and distribution of drugs.

## 2. Current Challenges Facing the Pharmaceutical Industry

### 2.1 Regulatory and Compliance Issues

- Complex and varied regulatory environments across different countries and regions
- Pressure for faster drug approvals while maintaining safety standards
- Intellectual property challenges, including patent expirations and generics

### 2.2 Cost and Pricing Pressures

- High costs of drug development and the pricing of new treatments
- Access to medicines in low- and middle-income countries
- Ethical issues surrounding the pricing of life-saving drugs

### 2.3 Public Health Crises and Pandemic Response

- The COVID-19 pandemic as a case study in the industry's ability to respond
- Vaccine development and distribution challenges
- Antimicrobial resistance (AMR) and the need for new antibiotics

### 2.4 Technological Disruptions

- The role of artificial intelligence (AI) and machine learning in drug discovery
- Data privacy and security issues in pharmaceutical research
- The integration of digital health technologies, such as wearables and telemedicine, with traditional pharmaceuticals

### 2.5 Environmental and Sustainability Concerns

- Green chemistry and the environmental impact of pharmaceutical production
- Sustainable packaging, waste management, and reducing carbon footprints in manufacturing
- Addressing the disposal and contamination of pharmaceutical residues in water supplies

### 3. Strategies for Overcoming Challenges

#### 3.1 Innovation and Research & Development (R&D)

- Fostering a culture of innovation through collaboration and partnerships with academic institutions and startups
- Emphasizing personalized medicine and genomics to create more effective, targeted treatments
- Leveraging AI and data analytics to streamline drug discovery and development processes

#### 3.2 Strengthening Regulatory Harmonization

- Enhancing global cooperation on regulatory standards and processes
- Improving transparency and communication between regulatory bodies and pharmaceutical companies
- Addressing the ethical issues surrounding drug approval and access

#### 3.3 Addressing Global Health Inequities

- Expanding access to affordable medicines through innovative pricing models and partnerships with international organizations
- Focusing on neglected diseases and increasing the availability of treatments for underrepresented populations
- Building local manufacturing capacity in developing countries to reduce dependency on global supply chains

#### 3.4 Sustainability and Green Practices

- Implementing eco-friendly manufacturing practices, such as waste minimization, energy efficiency, and renewable energy use
- Developing biodegradable packaging solutions and reducing plastic waste
- Fostering partnerships with environmental organizations to improve sustainability in pharmaceutical operations

#### 3.5 Workforce and Talent Development

- Adapting to the changing skill requirements in an increasingly digital pharmaceutical industry
- Ensuring workforce diversity and inclusion in pharmaceutical R&D and leadership roles
- Investing in training and development to equip employees with the necessary skills to innovate and address new challenges.

### III. OBJECTIVE

The primary objective of this study is to comprehensively examine the evolution of the global pharmaceutical industry, identify the key challenges it faces in the modern era, and propose strategies that can help stakeholders in the industry, including pharmaceutical companies, governments, and global organizations, navigate these challenges effectively. The study aims to provide insights into how the industry can evolve to meet current and future demands in healthcare, while also addressing its social, economic, and environmental responsibilities. Specifically, the objectives include:

1. To Analyze the Evolution of the Pharmaceutical Industry:
  - a. Examine the historical development of the pharmaceutical industry, focusing on key innovations, technological advancements, and regulatory changes.
  - b. Understand the transition from traditional medicines to modern pharmacology, including the rise of biotechnology, and the global expansion of pharmaceutical companies.
  - c. Assess the impact of globalization on the pharmaceutical supply chain, research, and distribution.
2. To Identify the Key Challenges Facing the Pharmaceutical Industry Today:
  - a. Investigate the complex regulatory frameworks across different regions and the impact of non-harmonized drug approval processes on global drug accessibility.
  - b. Explore the rising costs of drug development, pricing pressures, and the challenges related to pricing strategies, especially in low- and middle-income countries.
  - c. Analyze the pharmaceutical industry's response to public health crises, such as the COVID-19 pandemic, and ongoing challenges like antimicrobial resistance (AMR).
  - d. Examine the role of technological disruptions, such as artificial intelligence (AI) and data privacy, in shaping the future of drug discovery and development.
  - e. Address the environmental sustainability issues associated with pharmaceutical manufacturing, waste, and packaging.
3. To Propose Strategic Solutions and Recommendations:
  - a. Propose innovative strategies for pharmaceutical companies to foster research and development (R&D) and bring new, effective treatments to market more efficiently.

- b. Recommend strategies for harmonizing global regulations to facilitate faster drug approval and ensure drug safety and efficacy across borders.
  - c. Suggest approaches to enhance global access to medicines, particularly in underserved populations, and promote equitable pricing models.
  - d. Explore sustainable practices and eco-friendly technologies that can help reduce the environmental footprint of pharmaceutical production.
  - e. Provide insights into the workforce development needed to address the future challenges of an increasingly digital and globally interconnected pharmaceutical industry.
4. To Examine the Socioeconomic Impact of the Pharmaceutical Industry:
    - a. Assess the role of the pharmaceutical industry in driving economic growth, creating jobs, and improving healthcare outcomes globally.
    - b. Evaluate the industry's contribution to global health equity and the social implications of unequal access to essential medicines.
  5. To Examine the Role of Technology in Shaping the Pharmaceutical Industry:
    - a. Assess the impact of artificial intelligence (AI), machine learning, big data analytics, and digital platforms in revolutionizing drug discovery, clinical trials, and supply chain management.
    - b. Explore the role of precision medicine and genomics in personalizing treatment strategies.
  6. To Investigate Ethical and Social Implications of Pharmaceutical Practices:
    - a. Analyze ethical concerns related to drug pricing, patent protections, and marketing practices.
    - b. Examine the impact of corporate social responsibility (CSR) initiatives in enhancing public trust and improving health equity.
  7. To Evaluate Regional Disparities in Pharmaceutical Innovation and Access:
    - a. Study the differences in R&D activities, regulatory frameworks, and access to medicines across developed and developing nations.
    - b. Investigate barriers to healthcare equity, including infrastructure gaps, affordability issues, and geopolitical factors.
  8. To Assess the Environmental Impact of the Pharmaceutical Industry:
    - a. Explore the ecological footprint of pharmaceutical manufacturing processes, including chemical waste and energy consumption.
    - b. Evaluate the role of sustainable practices in mitigating environmental harm and promoting green pharmaceutical production.
  9. To Analyse Collaborative Models in Global Health:
    - a. Examine partnerships between pharmaceutical companies, governments, non-governmental organizations (NGOs), and international health bodies.
    - b. Assess the effectiveness of collaborative initiatives in addressing public health crises and improving global health outcomes.
  10. To Propose Policy Recommendations for a Resilient Pharmaceutical Industry:
    - a. Suggest reforms in regulatory processes to streamline drug approval while ensuring safety and efficacy.
    - b. Recommend policy frameworks to balance innovation incentives with the need for affordable and accessible medicines globally.

#### **IV. RESEARCH METHODOLOGY**

The research methodology outlines the systematic approach that will be used to address the objectives of the study. It involves a blend of qualitative and quantitative methods to provide a comprehensive understanding of the pharmaceutical industry's evolution, challenges, and strategies. The following methodology will guide the research process:

##### **1. Research Design**

This study will adopt an exploratory and descriptive research design. It aims to explore the historical evolution of the pharmaceutical industry, describe the challenges it currently faces, and evaluate the strategies being employed to navigate these challenges. The research will focus on the global perspective of the industry, analyzing both developed and developing regions.

## 2. Data Collection Methods

### 2.1 Primary Data Collection

#### a. Surveys and Questionnaires:

- Surveys will be distributed to pharmaceutical industry professionals (R&D specialists, regulatory experts, corporate strategists, etc.) and stakeholders (e.g., health economists, policymakers).
- The survey will assess their views on the current challenges, strategies for innovation, and regulatory issues facing the industry. Specific focus will be placed on how they perceive the industry's evolution and the impact of new technologies like AI and biotechnology on future developments.
- The questionnaires will consist of both closed-ended questions (to gather quantitative data) and open-ended questions (to gather qualitative insights).

#### b. Expert Interviews:

- In-depth interviews will be conducted with experts in the pharmaceutical industry, such as senior managers from pharmaceutical companies, healthcare policymakers, regulatory bodies (e.g., FDA, EMA), and academics in pharmaceutical sciences.
- The interviews will provide qualitative insights into the key challenges the industry faces and will allow experts to propose strategies for overcoming them.

### 2.2 Secondary Data Collection

#### a. Literature Review:

- An extensive review of existing literature (journals, articles, books, white papers, and reports) will be conducted to gather historical data on the pharmaceutical industry's evolution. Key sources will include academic journals, industry reports, and case studies on significant pharmaceutical advancements.
- The literature will cover various topics such as regulatory frameworks, drug development, pricing models, public health crises (e.g., COVID-19), and sustainable practices in the pharmaceutical industry.

#### b. Industry Reports and Publications:

- Reports from organizations such as the World Health Organization (WHO), McKinsey & Company, Pharmaceutical Research and Manufacturers of America (PhRMA), and government health agencies will be analyzed to gain a deeper understanding of the current state of the pharmaceutical industry, global trends, and challenges.
- Annual reports from major pharmaceutical companies will be reviewed to analyze how they are adapting to global challenges and incorporating new technologies.

#### c. Case Studies:

- Specific case studies related to major pharmaceutical innovations, public health responses (e.g., vaccine distribution during COVID-19), and sustainability practices will be reviewed to understand real-world applications of industry strategies.

## 3. Data Analysis Methods

### 3.1 Quantitative Analysis

- The survey data collected through questionnaires will be analyzed using statistical techniques. Descriptive statistics, such as mean, median, and mode, will be used to summarize the data, and inferential statistics, such as correlation and regression analysis, will be employed to identify relationships between different variables (e.g., the impact of regulatory changes on drug development timelines).
- Software such as SPSS or R will be used to analyze survey responses and produce statistical results.

### 3.2 Qualitative Analysis

- Interviews will be transcribed and analyzed using thematic analysis to identify key themes and patterns in responses related to challenges, strategies, and industry evolution.
- Thematic coding will be employed to categorize responses and draw meaningful conclusions from the expert opinions.



- NVivo or similar qualitative data analysis software will be used to facilitate the coding process and assist in organizing large volumes of interview data.

### 3.3 Comparative Analysis

- A comparative analysis will be conducted between the pharmaceutical industry's evolution in different geographical regions (e.g., North America, Europe, and developing countries) to understand regional variations in challenges, regulations, and industry strategies.
- Case studies from different pharmaceutical companies will also be compared to evaluate how industry leaders address key issues.

## 4. Research Scope and Limitations

### 4.1 Scope of the Study

- This study will focus on the global pharmaceutical industry, with particular attention to the developments in major pharmaceutical markets such as the United States, Europe, and Asia.
- Key areas covered will include the pharmaceutical R&D process, regulatory issues, drug pricing models, technological innovations, and sustainability practices.

### 4.2 Limitations

- The study may be limited by access to proprietary data from pharmaceutical companies, as well as the willingness of experts to participate in interviews or surveys.
- The evolving nature of global healthcare regulations may mean that some findings may become outdated or subject to future changes, especially in light of new technological advances or public health events (e.g., pandemics).
- Regional differences in data availability and reliability could impact the generalizability of findings.

## 5. Ethical Considerations

- Informed Consent: Participants in surveys and interviews will be provided with detailed information about the study's purpose, ensuring that they give informed consent before participating.
- Confidentiality: All survey and interview data will be kept confidential, and no personal identifying information will be disclosed in the final research.
- Non-bias: The research will be conducted with impartiality, ensuring that findings and conclusions are based on the data collected, rather than preconceived notions.

## REFERENCES

1. Cohen, J. (2022). "Pharmaceutical Innovation and Global Health: Challenges and Solutions." *Journal of Health Policy & Research*.
2. Gottfried, J. (2021). "Pharmaceutical Industry Evolution and Innovation." *International Journal of Pharmaceutical Sciences*.
3. World Health Organization (WHO). (2023). "Global Health and Pharmaceutical Industry: Policy and Practice."
4. God lee, F., et al. (2019). "The Development of Pharmaceutical Industry in the 20th Century." *International Journal of Pharmaceutical Sciences*.
5. Gupta, A., et al. (2021). "Global Health Responses: The COVID-19 Vaccine Challenge." *Lancet Global Health*.
6. Harris, T. (2022). "Regulatory Challenges in the Global Pharmaceutical Industry." *Pharmaceutical Policy Journal*.
7. Kumar, R., & Singh, M. (2021). "Innovations in Drug Discovery and Development." *Biotechnology Advances*.
8. McKinsey & Company. (2023). "The Rising Costs of Drug Development: Trends and Insights." *McKinsey Report*.
9. Robinson, R., et al. (2021). "Global Health and Equity in Pharmaceutical Access." *Global Health Review*.
10. Angeli, F., & Jaiswal, A. K. (2016). "Business model innovation for inclusive health care delivery at the bottom of the pyramid." *Journal of Business Research*, 69(5), 1840-1849.
11. DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). "Innovation in the pharmaceutical industry: New estimates of R&D costs." *Journal of Health Economics*, 47, 20-33.
12. Wouters, O. J., McKee, M., & Luyten, J. (2020). "Estimated research and development investment needed to bring a new medicine to market, 2009–2018." *JAMA*, 323(9), 844-853.
13. Kaitin, K. I., & Milne, C. P. (2011). "A deconstruction of the drug development process: The new face of innovation." *Clinical Pharmacology & Therapeutics*, 87(3), 356-361.

14. Paul, S. M., et al. (2010). "How to improve R&D productivity: The pharmaceutical industry's grand challenge." *Nature Reviews Drug Discovery*, 9(3), 203-214.
15. Hill, C. W. L., & Jones, G. R. (2021). *Strategic Management: Theory: An Integrated Approach*.
16. Roy, J. (2020). *Pharmaceutical Marketing: Principles, Environment, and Practice*.
17. Angell, M. (2004). *The Truth About the Drug Companies: How They Deceive Us and What to Do About It*.
18. Golec, J., & Vernon, J. A. (2010). *Pharmaceutical Economics and Public Policy*.



INTERNATIONAL  
STANDARD  
SERIAL  
NUMBER  
INDIA



# INTERNATIONAL JOURNAL OF INNOVATIVE RESEARCH

IN SCIENCE | ENGINEERING | TECHNOLOGY

 9940 572 462  6381 907 438  [ijirset@gmail.com](mailto:ijirset@gmail.com)



[www.ijirset.com](http://www.ijirset.com)

Scan to save the contact details